SG11201907927SA - Binding molecules that specifically bind to tau - Google Patents

Binding molecules that specifically bind to tau

Info

Publication number
SG11201907927SA
SG11201907927SA SG11201907927SA SG11201907927SA SG 11201907927S A SG11201907927S A SG 11201907927SA SG 11201907927S A SG11201907927S A SG 11201907927SA SG 11201907927S A SG11201907927S A SG 11201907927SA
Authority
SG
Singapore
Prior art keywords
international
archimedesweg
leiden
binding molecules
pct
Prior art date
Application number
Other languages
English (en)
Inventor
Jaroslaw Juraszek
Constantin Apetri
Original Assignee
Janssen Vaccines & Prevention Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Vaccines & Prevention Bv filed Critical Janssen Vaccines & Prevention Bv
Publication of SG11201907927SA publication Critical patent/SG11201907927SA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/2814Dementia; Cognitive disorders
    • G01N2800/2821Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Psychiatry (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
SG11201907927S 2017-03-28 2018-03-27 Binding molecules that specifically bind to tau SG11201907927SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17163425 2017-03-28
PCT/EP2018/057770 WO2018178077A1 (en) 2017-03-28 2018-03-27 Binding molecules that specifically bind to tau

Publications (1)

Publication Number Publication Date
SG11201907927SA true SG11201907927SA (en) 2019-10-30

Family

ID=58448491

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201907927S SG11201907927SA (en) 2017-03-28 2018-03-27 Binding molecules that specifically bind to tau

Country Status (10)

Country Link
US (1) US11028157B2 (de)
EP (1) EP3601335A1 (de)
JP (1) JP7109467B2 (de)
KR (1) KR20190133191A (de)
CN (1) CN110418804A (de)
AU (1) AU2018241857A1 (de)
CA (1) CA3056517A1 (de)
EA (1) EA201992281A1 (de)
SG (1) SG11201907927SA (de)
WO (1) WO2018178077A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10501531B2 (en) 2013-03-13 2019-12-10 Prothena Biosciences Limited Tau immunotherapy
PE20190261A1 (es) 2016-05-02 2019-02-25 Prothena Biosciences Ltd Anticuerpos que reconocen tau
US10752679B2 (en) 2016-05-02 2020-08-25 Prothena Biosciences Limited Tau immunotherapy
CN110520440A (zh) 2017-02-17 2019-11-29 戴纳立制药公司 抗τ抗体及其使用方法
PE20200695A1 (es) 2017-05-02 2020-06-16 Prothena Biosciences Ltd Anticuerpos que reconocen tau
CA3131531A1 (en) 2019-03-03 2020-09-10 Prothena Biosciences Limited Antibodies recognizing tau
GB201909393D0 (en) * 2019-06-28 2019-08-14 Gen2 Neuroscience Ltd Tau epitope and binding molecules
WO2023092004A1 (en) 2021-11-17 2023-05-25 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1161548E (pt) 1999-04-15 2005-06-30 Crucell Holland Bv Producao de proteinas recombinantes numa celula humana utilizando sequencias codificando a proteina e1 de adenovirus
WO2012049570A1 (en) * 2010-10-11 2012-04-19 Panima Pharmaceuticals Ag Human anti-tau antibodies
WO2012149365A2 (en) 2011-04-27 2012-11-01 Northwestern University Antibodies selective for pathological tau dimers and prefibrillar pathological tau oligomers and their uses in treatment, diagnosis and monitoring of tauopathies
DK2758433T3 (en) 2011-09-19 2018-01-15 Axon Neuroscience Se PROTEIN-BASED THERAPY AND DIAGNOSIS OF TAU-MEDIATED PATHOLOGY OF ALZHEIMER'S DISEASE
ZA201608812B (en) * 2014-06-26 2019-08-28 Janssen Vaccines & Prevention Bv Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
WO2015197823A2 (en) * 2014-06-26 2015-12-30 Crucell Holland B.V. Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
SG11201703237VA (en) 2014-11-19 2017-06-29 Axon Neuroscience Se Humanized tau antibodies in alzheimer's disease

Also Published As

Publication number Publication date
US11028157B2 (en) 2021-06-08
EP3601335A1 (de) 2020-02-05
US20210122810A1 (en) 2021-04-29
KR20190133191A (ko) 2019-12-02
EA201992281A1 (ru) 2020-02-13
CA3056517A1 (en) 2018-10-04
CN110418804A (zh) 2019-11-05
JP2020511976A (ja) 2020-04-23
JP7109467B2 (ja) 2022-07-29
WO2018178077A1 (en) 2018-10-04
AU2018241857A1 (en) 2019-09-19

Similar Documents

Publication Publication Date Title
SG11201907927SA (en) Binding molecules that specifically bind to tau
SG11201811003PA (en) Anti-pd-l1 antibodies and uses thereof
SG11201811432WA (en) Rna for cancer therapy
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201900480YA (en) Anti-tim-3 antibodies
SG11201807912SA (en) Vaccine against rsv
SG11201908919XA (en) Combination therapies targeting pd-1, tim-3, and lag-3
SG11201807401RA (en) Therapeutic membrane vesicles
SG11201810927QA (en) Pd-l1-specific antibodies and methods of using the same
SG11201908325PA (en) Process for the preparation of glucuronide drug-linkers and intermediates thereof
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201408780XA (en) Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
SG11201809374VA (en) Cd40l-fc fusion polypeptides and methods of use thereof
SG11201807827VA (en) Process for the preparation of pegylated drug-linkers and intermediates thereof
SG11201403106SA (en) Anti-phf-tau antibodies and their uses
SG11201907208XA (en) Radiolabeled anti-lag3 antibodies for immuno-pet imaging
SG11201807523PA (en) Ilt7 binding molecules and methods of using the same
SG11201803692PA (en) Anti-5t4 antibodies and antibody-drug conjugates
SG11201909680UA (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
SG11201804704PA (en) Compositions and methods for decreasing tau expression
SG11201408037SA (en) Humanized anti-trka antibodies with amino acid substitutions
SG11201810801QA (en) Brain delivery protein
SG11201809882XA (en) Pharmaceutical combinations for treating cancer
SG11201807062RA (en) Anti-tnfalpha-antibodies and functional fragments thereof